A strategic investment by Samsung Ventures in Araris Biotech Ltd

18. April 2023

Samsung Ventures made a strategic investment in Araris Biotech Ltd who was advised by BGPartner. 

Araris Biotech Ltd, a company pioneering antibody-drug conjugate (ADC) linker technology, intends to use the proceeds to support further development and advancement of Araris’ antibody-drug conjugate (ADC) candidates.

BGPartner assisted Araris Biotech Ltd in the negotiations and advised on all Swiss legal matters regarding this strategic investment. The team was led by Oliver Gnehm (Partner) and further consisted of Thomas Gysin (Senior Associate).

The official press release from Araris Biotech Ltd can be found here.

More information about our negotiation expertise can be found here.